Patents Examined by Matthew P Coughlin
  • Patent number: 11731952
    Abstract: The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: August 22, 2023
    Assignees: MUSC Foundation for Research Development, Lukogene Therapeutics Incorporated
    Inventors: Nathan G. Dolloff, Reeder M. Robinson, Allen B. Reitz, Haiyan Bian
  • Patent number: 11725018
    Abstract: Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: August 15, 2023
    Assignee: Aeromics, Inc.
    Inventors: Paul Robert McGuirk, Robert Zamboni, Melanie Bevill, Stephan Parent
  • Patent number: 11717471
    Abstract: The present application provides hydrogel microcapsules, particularly, canonized hydrogel microcapsules having improved substantivity. This application further relates to the use of hydrogel microcapsules for delivering encapsulated actives in a wide range of industries and applications including: agrochemicals, pharmaceuticals, cosmetics industry, personal care products, laundering detergents, homecare & cleaning products, dish washing detergents, oral care, dental care, textiles, paper, mining, oil industry, water treatment, adhesives, coatings, plastics, sealants, construction, paints, inks and dyes onto different substrate surfaces such as skin, hair, textiles.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: August 8, 2023
    Assignee: ISP Investments LLC
    Inventors: Kishor Kumar Mistry, Abdul Wahab Hussain, Petra Helga Beck, David Vaughan Palmer, Benjamin Roger Sales, Andrew Mint
  • Patent number: 11718607
    Abstract: Presented herein is a coupling method for the preparation of 1,2-di(thiophen-2-yl)ethane-1,2-diol compounds, including (E)-1,2-di(thiophen-2-yl)ethene-1,2-diol, via a Cu(II) catalyst.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: August 8, 2023
    Assignee: QATAR UNIVERSITY
    Inventors: Ismail K. Warad, Amjad M. Shraim, Anas Al-Ali, Kifah S M Salih, Abdelkader Zarrouk, Yousef Hijji
  • Patent number: 11701330
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: July 18, 2023
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 11697652
    Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: July 11, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
  • Patent number: 11685711
    Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: June 27, 2023
    Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Ladie Kimberly c. De La Cruz, Xingyue Ji, Zhixiang Pan, Binghe Wang
  • Patent number: 11679182
    Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: June 20, 2023
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs, Robert Doyle
  • Patent number: 11680050
    Abstract: The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: June 20, 2023
    Assignee: RECEPTOS LLC
    Inventors: Minhua Chen, Xiaoyu Zhang, Yanfeng Zhang, Chaohui Yang, Xiaoting Zhai, Kaiqiang Yan
  • Patent number: 11679984
    Abstract: A colloidal dispersion of particles of silica having a particle size of from 3 nm to 100 nm, to which ions of one or more metals are adsorbed, selected from metals having atomic numbers 21-31, 39-46, 48-50, 57-82, and 89-93, and a method for preparing the dispersion. The dispersion may be used in various fields of use of metals.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: June 20, 2023
    Assignee: PREBONA AB
    Inventor: Jan-Erik Otterstedt
  • Patent number: 11672782
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: June 13, 2023
    Assignee: NOVARTIS AG
    Inventors: Kamlesh Jagdis Bala, Andrew Brearley, James Dale, Anne-Marie Edwards, Mahbub Ahmed, David Porter, Robert Alexander Pulz, Lisa Ann Rooney, David Andrew Sandham, Duncan Shaw, Nichola Smith, Jessica Louise Taylor, Roger John Taylor, Thomas Josef Troxler, Joe Wrigglesworth
  • Patent number: 11673866
    Abstract: 4-Hydroxyphenyl-2H-indazol-5-ol compounds are estrogen receptor beta ligands that have immunomodulatory properties and increase oligodendrocyte survival, differentiation, and remyelination. The compounds, compositions, and kits are useful in the treatment of multiple sclerosis and endometriosis.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: June 13, 2023
    Assignees: The Board of Trustees of the University of Illinois, The Regents of the University of California
    Inventors: John A. Katzenellenbogen, Seema K. Tiwari-Woodruff, Sung Hoon Kim, Benita Katzenellenbogen
  • Patent number: 11660270
    Abstract: Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: May 30, 2023
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Domb Abraham Jacob, Michael Kubek
  • Patent number: 11654116
    Abstract: A porous particle, wherein the porous particle has a mass median aerodynamic diameter and a volume average particle diameter that satisfy expression: y?2x, where x denotes the mass median aerodynamic diameter and y denotes the volume average particle diameter, and the porous particle has a relative span factor (R.S.F) that satisfies expression: 0<(R.S.F)?1.5.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: May 23, 2023
    Assignee: Ricoh Company, Ltd.
    Inventors: Naoki Shiraishi, Tatsuru Moritani, Yuichi Sato
  • Patent number: 11654292
    Abstract: Methods are provided for targeting cancer cells that over-express voltage-gated sodium channels (VGSCs or “sodium channels”) and causing osmotic lysis of these cancer cells by initially inhibiting the sodium, potassium-adenosine triphosphatase (Na+, K+-ATPase or “sodium pump”), and then stimulating the VGSCs by pulsed magnetic field gradients to cause sodium and water to enter the cancer cells.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: May 23, 2023
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Dennis J. Paul, Harry J. Gould, III
  • Patent number: 11655242
    Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: May 23, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Todd Fields, Joseph Daniel Ho, Fucheng Qu
  • Patent number: 11648249
    Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: May 16, 2023
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Charles Tokunbo Adesuyi, Bruce Hamilton Lithgow, Olivier Lambert, Lovelace Holman
  • Patent number: 11649220
    Abstract: The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol derivative provided in the present invention can be used for the prevention and treatment of vascular diseases including diabetes, cardio-cerebrovascular diseases or complications thereof, and can be effectively used for reducing blood glucose, reducing blood lipid, reducing cholesterol, reducing body weight, reducing triglyceride, anti-inflammatory, and anti-oxidation, etc., having broad prospective applications.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: May 16, 2023
    Assignee: DEMOTECH.INC.
    Inventors: Song Lu, Wenwei Xie, Shuangjiang He
  • Patent number: 11639338
    Abstract: A method by which an intermediate product of an azole derivative can be produced at a lower cost and in a higher yield than those of known production methods is realized. A method of producing a compound of General Formula (III) includes: producing the compound of General Formula (III) by allowing a cyanide compound to act on a ketone derivative of General Formula (II); and washing the compound of General Formula (III) produced in the producing the compound of General Formula (III) with an alkaline aqueous solution.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: May 2, 2023
    Assignee: Kureha Corporation
    Inventors: Shigeru Suzuki, Nobuyuki Kusano, Hisataka Kobayashi
  • Patent number: 11638712
    Abstract: The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of pancreatitis-related pain, IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), dry eye disease and conjunctivitis sicca. These inhibitors were found to have a different inhibitory profile compared to diphenyl guanidinophenylethylphosphonates leading to a more pronounced effect on these conditions.
    Type: Grant
    Filed: October 6, 2021
    Date of Patent: May 2, 2023
    Assignee: Universiteit Antwerpen
    Inventors: Koen Augustyns, Jurgen Joossens, Pieter Van Der Veken, Paul Cos, Cedric Joossen, Benedicte Yvonne De Winter, Hannah Ceuleers, Hanne Van Spaendonk